CO.DON AG
co.don Aktiengesellschaft: co.don AG wins Bauerfeind AG as new anchor investor
DGAP-News: co.don Aktiengesellschaft / Key word(s): Miscellaneous Press release co.don AG wins Bauerfeind AG as new anchor investor Dirk Hessel, CEO of co.don AG: “We are very pleased to have won Bauerfeind AG as a new entrepreneurial anchor investor with a long-term strategy. Bauerfeind AG has many years of international experience in the field of orthopaedics. There is a considerable overlap in our customer segments for innovative therapies. The synergies resulting from this strategic partnership will form a stable basis for continuing the implementation of our company’s ongoing growth strategy, both within Germany and in preparation for entering the wider EU market. We thank OSEMIFARO INVESTMENTS Ltd. and TRANSNOVA INVESTMENTS Ltd. for their support over many years.” “Joint preservation before joint replacement is co.don’s guiding principle. For me that is more than an idea that happens to chime with the current mood. In connection with our bandages and supports I see it as a fundamental approach for a holistic therapy”, explains Prof. Hans B. Bauerfeind.
Matthias Meißner, M.A. About Bauerfeind AG: Bauerfeind AG from Zeulenroda in Thuringia makes bandages, supports, medical compression tights and orthopaedic inserts. The family company was established in 1929, has international sales operations and is one of the market leaders. Bauerfeind has a total of around 2,500 employees, is based in Germany and has subsidiaries in more than 20 countries. Its premium products stand for quality “Made in Germany”. About co.don AG: Berlin-based co.don AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage to joints following traumatic or degenerative defects. co.don condrosphere(R) is a cell therapy product that uses only the patient’s own cartilage cells (“autologous chondrocytes”). co.don condrosphere(R) has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. co.don condrosphere(R) has been used for more than 10 years in over 120 clinics to treat more than 10,000 patients. The shares in co.don AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO), Vilma Methner (COO, CSO). Further informationen can be found at www.ihre-zellzuechter.de or www.codon.de
2016-07-13 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |
Language: | English | |
Company: | co.don Aktiengesellschaft | |
Warthestraße 21 | ||
14513 Teltow | ||
Germany | ||
Phone: | 03328 43460 | |
Fax: | 03328 434643 | |
E-mail: | info@codon.de | |
Internet: | www.codon.de | |
ISIN: | DE000A1K0227 | |
WKN: | A1K022 | |
Listed: | Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange | |
End of News | DGAP News Service |